Member Info for Basser1

Cuvio- whilst SRA 737 might not the main event at the moment, there is no doubt of its massive potential when working in combination with other small molecules. Quote from the Sareum RNS this August

‘In discussing the rationale for adding AZD5153 to its pipeline, Sierra referred to possible pipeline expansion opportunities in other haematologic or solid tumour indications, through potential combinations with SRA737, immune-oncology agents, PARP inhibitors and drugs with other mechanisms of action.”

And as John Reader, Sareum’s Chief Scientific Officer has pointed out in an earlier RNS
“ The combinations of SRA 737 and Adavosertib potential Ed cell death in cellular models of Ovarian, breast and Pancreatic Cancer and in disease model studies of ovarian and breast cancer. Sareum’s CSO Dr John Reader commented” we are encouraged to see yet another potential modality for SRA 737, in this case in tumours with a TP53 mutation, a mutation that is present in approximately half of all solid tumour cancers”.
There are twenty Solid Tumour cancers including Lung, Breast, Pancreatic , Liver, Kidney and Ovarian. Whilst it was expected we now know from the clinical trial date that SRA737 on its own has a good safety profile and demonstrates anti cancer activity. As such it seems to be tailor made to work in combination with a range of other small molecules. The potential here really is enormous.

Some hefty buys showing up this morning. Not reflected in the share price.

Steve - you will know that the annual results cover the period up to 30 June 2021. So why do you think the results will be any different from previous years? The company’s update on programme development (as much as can be released) will be for the Investor meeting a week later. I do wonder what your motive is here.

On Radio 4 this morning. Astra Zeneca vaccine is not as effective against the initial Delta variant. And the new variant may be up to 10% more spreadable. Focus will be back on Therapeutics as cases rise.

It’s clearly a buy

Ahfam you may be right. But given the current pressure on the share price I think the company would be slaughtered by shareholders if they were not making the most of this fantastic new development which has implications beyond just the company’s assets. I expect an RNS next week.

Zylo -OK. But surely it warrants an RNS because of the wider implications that this portrays? Sareum in its current circumstances quote “would want all the World to know”.

Num- I would have thought that this includes Cancers as well re SD1802?

Great find timbo 003 and MADD- RIP. We need to tread carefully here but is appears that this is the process being patented. Quote from Patent “ The foregoing examples are presented for the purpose of illustrating the invention and should not be construed as imposing any limitations on the scope of the invention. It will readily be apparent that numerous modifications and alterations may be made to the specific embodiments of the invention described above and illustrated in the examples without departing from the principles underlying the invention. All such modifications are intended to be embraced by this application”
All will be revealed in the inevitable RNS.

Over 500ks worth of shares traded - a 1000% VS Average volume. 2 hours of trading still left. Who knows but there may be an announcement soon about another combo trial with SRA737 - and if so hopefully keytruda.

My guess is an RNS by Sierra Oncology re SRA737 before the Wainwright Conference next Monday. Always wrong though. Interesting to see Sierra share activity today.

Interesting because there is no mention of Momelotinib. So at last we may get some news about expanding their pipeline to include combo trials with SRA 737. First conference on Monday 13th - HC Wainwright. Presentation by Stephen Dilley to provide company updates.

Inducement grants awarded to 5 new Sierra staff today. Sierra is certainly gearing up staff recruitment for widening its pipeline. Massive volume of trading earlier in the week and institutional funds trying to get in at lower price (similar to Sareum’s current pattern of trading). Could be a perfect storm of news soon with Sareum’s announcement of Covid treatment plan and Sierra announcement of SRA737 combo agreement to test promising findings in treatment of Small Cell Lung Cancer. An exciting couple of weeks ahead IMO. GLA long term holders.

a7 - can you let me know what deadlines Sareum has missed please that are of any significance to SDC1801 and SDC 1802?

Jobjobbed - quote from Sareum website re SDC1802 . SDC 1802 shows compelling efficacy in blocking cancer cell proliferation in cellular disease models of T Cell acute lymphoblastic leukaemia and B Cell Lymphoma. The potential for once a day dosing and good safety profile. Sareum has discovered encouraging evidence to suggest that these molecules can function as a cancer immunotherapy by modulating the host immune system to block tumour cell proliferation in disease models of kidney, colon, skin and pancreatic cancers.

Think you had better upped your expectations. 1802 is probably destined to be Sareum’s jewel in the crown and in my view is the coveted target of the big pharmas. You don’t get science like this on the cheap.

Gunner - there are contributors on here who know much more than me about the patent process. As for notifying progress on trials there is no reason why an interim RNS could not appear - stating who the covid partner is and that details of trial arrangements would follow. If you look at timing for next winter then it would seem to me that trials would need to start around late September so that an 8 week trial ends in late November. This would give time to organise logistics if trials are positive.

Gunner - 6 weeks to consult on best way forward and to draw up details of the Covid trial is not a long time,.Sareum do not rush into things. The company’s meticulous approach is the secret of its success. Think news will be before end of August and could come at any time now.

Stoney- as expected Artesunate, imatinib and infliximab all have potentially very serious side effects. SDC1801 with its low toxicity and tablet form and TYK 2 base has a lot going for it.

BoilB - I can understand your and many others frustration about how Sierra has been mishandled. But the company is not stupid- the many scientific papers supporting SRA737 in combination with other inhibitors is plain to see. As I have said before, the company are so aware of its potential ( Dilley even hinted at this in an RNS) that they have delayed its further advancement because it realises how big this news is and that they have not got the financial clout to take it forward - yet. It does not want to sell SRA737 on because why give up the prize that can give them real pharmaceutical status. What surprises me is that the licence amendment agreed last November has not revealed much evidence of a distinctly new approach for taking SRA737 forward. Is that because of the weakness of the revised agreement or is it that they are continuing to live close to the wire and potential litigation? I tend to think that it is not the latter as a litigation case by the much respected Cancer Research and its Uk ‘s Pioneer Fund would be very damaging to the company,s status in my opinion. The encouraging thing is that Sierra has been employing quite a number of new staff to provide the resources for extending the pipeline. It would make a massive statement if Sierra would come clean and state the importance of SRA737 in its pipeline and that it would be prioritising its future development. But it is stillplaying for time. It’s all about cash being available to take such an exciting combo project forward. They would rather delay than license it to some other pharma and that could be the weakness in the revised contract amendment.

http://www.sareum.com/news/press-releases-and-news/2021/research-update/

The reason why Thoth would wet himself! Me too!